Sellas Life Sciences

SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

Data accepted for oral presentation at the 43rd annual meeting of the European Society for Blood and Marrow Transplantation – Results underscore ability of SELLAS’s lead product candidate, galinpepimut-S, to target a broad range of cancer indications – HAMILTON, Bermuda,...
Read More →